Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Estrella Immunopharma, Inc. - Common Stock (NQ:ESLA)

1.222 -0.028 (-2.20%)

Streaming Delayed Price Updated: 12:12 PM EST, Feb 19, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	22,808
Open	1.300
Bid (Size)	1.190 (100)
Ask (Size)	1.280 (100)
Prev. Close	1.250
Today's Range	1.200 - 1.300
52wk Range	0.7301 - 3.150
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Monday's pre-market session: top gainers and losers ↗

February 09, 2026

Via Chartmill

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

February 09, 2026

From Estrella Immunopharma, Inc.

Via Business Wire

Performance

YTD	-12.1%	-12.1%
1 Month	+34.2%	+34.2%
3 Month	-30.1%	-30.1%
6 Month	+35.4%	+35.4%
1 Year	-15.1%	-15.1%

More News

Curious about the stocks that are showing activity after the closing bell on Friday? ↗

February 06, 2026

Via Chartmill

Here are the top movers in Thursday's session. ↗

February 05, 2026

Via Chartmill

Thursday's session: top gainers and losers ↗

February 05, 2026

Via Chartmill

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

February 03, 2026

From Estrella Immunopharma, Inc.

Via Business Wire

BioMedNewsBreaks – Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) Closes $8.0 Million Registered Direct Offering

January 07, 2026

Via Investor Brand Network

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

January 06, 2026

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

January 05, 2026

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

December 04, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Tuesday's session: top gainers and losers ↗

November 04, 2025

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 04, 2025

Via Benzinga

Which stocks are moving on Monday? ↗

November 03, 2025

Via Chartmill

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

November 03, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 22, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 14, 2025

Via Benzinga

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

October 06, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

June 05, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

June 03, 2025

Via Benzinga

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

June 03, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas

May 29, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

March 05, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week ↗

February 23, 2025

Via Stocktwits

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

February 21, 2025

From Estrella Immunopharma

Via Business Wire

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

February 19, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Frequently Asked Questions

Is Estrella Immunopharma, Inc. - Common Stock publicly traded?

Yes, Estrella Immunopharma, Inc. - Common Stock is publicly traded.

What exchange does Estrella Immunopharma, Inc. - Common Stock trade on?

Estrella Immunopharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Estrella Immunopharma, Inc. - Common Stock?

The ticker symbol for Estrella Immunopharma, Inc. - Common Stock is ESLA on the Nasdaq Stock Market

What is the current price of Estrella Immunopharma, Inc. - Common Stock?

The current price of Estrella Immunopharma, Inc. - Common Stock is 1.222

When was Estrella Immunopharma, Inc. - Common Stock last traded?

The last trade of Estrella Immunopharma, Inc. - Common Stock was at 02/19/26 12:12 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.